Home » Proposed Rule Would Change Names of Six Biologicals, Including Neupogen
Proposed Rule Would Change Names of Six Biologicals, Including Neupogen
September 8, 2015
Just days before Sandoz launched Zarxio, its biosimilar of Amgen’s chemotherapy drug Neupogen, the U.S. Food and Drug Administration issued a proposed rule changing both drugs’ official names, at least temporarily.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor